Latest news with #KimThompson
Associated Press
03-06-2025
- Business
- Associated Press
24/7 Market News - Kraig Biocraft Advances Toward First-Ever Spider Silk Deliveries to Luxury and Performance Giants
Shareholder Letter Reveals Breakthroughs, Global Brand Engagement, and Commercial Readiness Denver, Colorado--(Newsfile Corp. - June 3, 2025) - a pioneer in digital media dedicated to the swift distribution of financial market news and information, features the key highlights from a compelling shareholder letter by Kim Thompson, the CEO of Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk. The letter detailed groundbreaking scientific advancements, robust production progress, and a commercial pivot toward high-profile global partnerships, including these key takeaways: [ This image cannot be displayed. Please visit the source: ] Kraig Biocraft Laboratories Logo Global Brands Standing by for First Spider Silk Shipments Kraig Labs entered active commercial discussions with three major global brands that are preparing to receive initial spider silk shipments. 'We are in regular communication with three major global brands that are standing by to receive their first shipments of materials,' the letter stated. These include: 'Currently, we expect to begin deliveries to these customers in the second half of this year.' New Double Hybrid Strain on Track for 2025 Launch A major scientific milestone was confirmed with the announcement that the Company's next-generation production model—the double hybrid system—remains fully on track for deployment in 2025, which is critical to launching its double hybrid system, marking a significant leap in scalability and efficiency. 'Our longstanding plans were to field a new strain of silkworm for our double hybrid production system in the Summer of 2025... We were, therefore, ecstatic to announce that we created another world's first development on schedule.' This breakthrough is expected to boost production output by 25% or more monthly. 'The double hybrid model is designed to significantly improve our silk production rate, we expect by as much as 25+% per month.' [ This image cannot be displayed. Please visit the source: ] Kraig Lab BAM-1 Recombinant Spider Silk Cocoons BAM-1 Hybrid Demonstrates Industry-Leading Resilience Kraig Biocraft's current BAM-1 hybrid system has already delivered major gains in disease resistance and reliability, matching the robustness and disease tolerance of the Chinese commercial silk hybrid, the regional gold standard. 'The BAM-1 appears to be on par with the Chinese commercial silk hybrid, which is the gold standard in that region for the production of mundane silk.' This leap in robustness has mitigated previous challenges with silkworm diseases and environmental stress. This resilience ensures more reliable production cycles, even in difficult environmental conditions like the current rainy season affecting global silk producers. 'Since rolling out the BAM-1, we have dealt with these routine challenges and have weathered these events with similar or identical effects as mundane silk producers utilizing the Chinese hybrid.' Work-in-Progress Inventory to Reflect True Output The Company confirmed that several hundred kilograms of recombinant spider silk cocoon are now awaiting to be processed into finished silk. Kraig will begin including this in its work-in-progress (WIP) inventory accounting, to better reflect the company's shift to larger-scale production. 'We will expand the scope of our work-in-progress (WIP) material inventory to include recombinant spider silk cocoon that has been completed but not reeled.' This shift comes as hundreds of kilograms of spider silk cocoons await processing, laying the groundwork for larger-scale deliveries. 'In the first quarter of this year, we stockpiled several hundred kilograms of cocoon that are now waiting to be processed into finished silk.' This inventory expansion marks a transition from nominal production to commercial-scale operations. Spider Silk Technology at a Tipping Point The past year has seen what the Company describes as a 'revolution' in its spider silk production technology. 'In short, there has been a revolution in our spider silk production technology over the past 14 months due to the introduction of BAM-1 and other improvements in the field and laboratory.' Robust strain development, improved disease tolerance, and steady production have laid the groundwork for scalable, high-yield manufacturing. 'As we meet our marks toward the initiation of the double hybrid, we anticipate our gains to accelerate further.' Commercial Focus and Execution at the Forefront The letter also emphasized that spider silk production remains Kraig's exclusive and that execution is rapidly accelerating. 'In the last 8-10 months, we've been able to move faster to deliver on that commitment.' Revolution in Spider Silk Production: Over the past 14 months, Kraig Labs has achieved a 'revolution' in its spider silk technology, overcoming historical robustness issues and positioning the company for accelerated growth as it prepares for the double hybrid system rollout. The combination of scientific breakthroughs, increased output, and major brand engagement positions Kraig Biocraft for commercial revenue generation. Focused Execution and Commercial Outlook CEO Kim Thompson concluded the letter with a reaffirmation of Kraig Labs' unwavering mission: 'We are 100% focused on the production of spider silk for commercial delivery. Over the last year, we've been able to move faster to deliver on that commitment.' 'I believe the future for Kraig Labs and spider silk has never been brighter, and we thank you for your continued support.' Kraig emphasized that 100% of its focus is on spider silk production, and that accelerated progress over the past 8-10 months has positioned the company for its most important year yet. With foundational technology in place, the path to scaled commercialization and revenue generation is clearer than ever. With next-gen technology on schedule, scaled inventory building underway, and three industry giants preparing to receive initial shipments, Kraig Biocraft Laboratories is transitioning from a research-centric biotech into a commercially viable materials science innovator. Please click here for the full letter. About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications. For more information, please visit: Please click here to read the full Kraig Labs analyst report on Contact [email protected] for Analyst Report coverage and other investor/public relations services. 24/7 MARKET NEWS, INC Disclaimer Please go to for disclaimer information. About 24/7 Market News 24/7 Market News is a leading platform for public company market news. As a pioneer in digital media, we are committed to the rapid dissemination of financial market news and information. We excel in creating innovative public relations campaigns to help our clients effectively reach their target audience. 24/7 Market News offers paid coverage for public companies. For more information or PR inquiries, please contact: [email protected] Please go to for further information. CONTACT: 24/7 Market News [email protected] Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, the popularity and/or competitive success of the Company's acquired football and other sports teams, the Company's ability to attract players and staff for acquired clubs, unsuccessful acquisitions or other strategic transactions, the possibility of a decline in the popularity of football or other sports, the Company's ability to expand its fanbase, sponsors and commercial partners, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. To view the source version of this press release, please visit
Associated Press
28-05-2025
- Business
- Associated Press
Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain for Expanded Commercial Production
ANN ARBOR, Mich., May 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ('Company' or 'Kraig Labs'), a world leader in spider silk technology*, announces today the successful development of a new recombinant spider silk parental line, purpose-built for large-scale commercial production. This newly developed strain represents the third commercial production line created by Kraig Labs as it executes on its strategy to expand output capacity. The addition of this next-generation silk-producing line comes as the Company ramps up production to fulfill current material requests and strategically build inventory for future sales. 'Our team continues to deliver on key milestones as we scale the commercialization of spider silk,' said Company Founder and CEO, Kim Thompson. 'With the development of this new production strain, we are not only increasing our ability to meet existing demand, but also reinforcing the foundation for our future growth. This new strain is part of the production roadmap we outlined in 2024 and a key part of our transition to a full double hybrid production system.' This latest strain is part of Kraig Labs' broader development pipeline, which includes several additional parental lines currently in advanced stages of development. These lines are designed to enable a transition to a double hybrid production model—expected to deliver significant performance improvements, including higher silk yields, increased colony resilience, and reduced overall production costs. 'As we prepare to implement double hybrid crosses into our production platform, we are opening the door to greater scalability, efficiency, and product consistency,' Thompson continued. 'This is a key step forward in our mission to bring the power of spider silk to mainstream markets.' The Company is continuing its focus on building a robust and scalable production system as it transitions from pilot operations to full-scale manufacturing. For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit . For details about other recent Kraig Labs advancements, please watch the Company's investor conference at or on the Company's YouTube Channel . To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to * For a description of our historical leadership in this technology, please follow this link About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. ( ), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company's future and expectations other than historical facts are 'forward-looking statements.' These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as 'believes,' 'plans,' 'expects,' 'anticipates,' 'foresees,' 'estimated,' 'hopes,' 'if,' 'develops,' 'researching,' 'research,' 'pilot,' 'potential,' 'could' or other words or phrases of similar import. Forward-looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. Ben Hansel, Hansel Capital, Inc. (720) 288-8495 [email protected]
Yahoo
28-05-2025
- Business
- Yahoo
Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain for Expanded Commercial Production
Company Expands Capacity to Meet Material Demand and Scale Inventory by developing new parental Strain for Production ANN ARBOR, Mich., May 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces today the successful development of a new recombinant spider silk parental line, purpose-built for large-scale commercial production. This newly developed strain represents the third commercial production line created by Kraig Labs as it executes on its strategy to expand output capacity. The addition of this next-generation silk-producing line comes as the Company ramps up production to fulfill current material requests and strategically build inventory for future sales. "Our team continues to deliver on key milestones as we scale the commercialization of spider silk," said Company Founder and CEO, Kim Thompson. "With the development of this new production strain, we are not only increasing our ability to meet existing demand, but also reinforcing the foundation for our future growth. This new strain is part of the production roadmap we outlined in 2024 and a key part of our transition to a full double hybrid production system." This latest strain is part of Kraig Labs' broader development pipeline, which includes several additional parental lines currently in advanced stages of development. These lines are designed to enable a transition to a double hybrid production model—expected to deliver significant performance improvements, including higher silk yields, increased colony resilience, and reduced overall production costs. "As we prepare to implement double hybrid crosses into our production platform, we are opening the door to greater scalability, efficiency, and product consistency," Thompson continued. "This is a key step forward in our mission to bring the power of spider silk to mainstream markets." The Company is continuing its focus on building a robust and scalable production system as it transitions from pilot operations to full-scale manufacturing. For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit For details about other recent Kraig Labs advancements, please watch the Company's investor conference at or on the Company's YouTube Channel To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to * For a description of our historical leadership in this technology, please follow this link About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. ( a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward-looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. Ben Hansel, Hansel Capital, Inc.(720) 288-8495ir@ in to access your portfolio
Yahoo
06-05-2025
- Business
- Yahoo
Kraig Biocraft Laboratories Successfully Completes March
Kraig Biocraft Laboratories Company Continues to Meet 2025 Scale-Up Targets ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it has successfully completed its March/April spider silk production run and is currently well underway with its May production cycle. Kraig Labs Recombinant Spider Silk Cocoons This steady progress reflects the Company's continued execution against its 2025 production scale-up plan, which builds on the significant operational and technical advancements achieved throughout 2024. Spider silk production for March and April met internal performance benchmarks and production targets, reinforcing confidence in the expanded capacity and workflow improvements implemented earlier this year. With May's production already in progress, Kraig Labs is maintaining its momentum and remains on track to meet its full-year production capacity goals. These efforts support Kraig Labs' broader strategy to transition recombinant spider silk from pilot-scale production to commercial viability across multiple markets. "Our teams in Vietnam and the U.S. continue to demonstrate consistent execution and focus," said Company Founder and CEO, Kim Thompson. "With each completed cycle, we are strengthening our manufacturing capabilities and moving closer to our goal of delivering commercial volumes of eco-friendly, performance fiber." The Company will provide further updates as it progresses through its 2025 production calendar. For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit For details about other recent Kraig Labs advancements, please watch the Company's investor conference at or on the Company's YouTube Channel To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to * For a description of our historical leadership in this technology, please follow this link About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. ( ), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Cautionary Statement Regarding Forward Looking Information
Associated Press
10-02-2025
- Business
- Associated Press
Kraig Biocraft Laboratories Unveils Groundbreaking Scientific Achievement Based on Caddisfly Silk Proteins
ANN ARBOR, Mich., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ('the Company' or 'Kraig Labs'), a leading developer of spider silk-based fibers, proudly announces the successful creation of new novel silk, build upon the silk proteins of the remarkable caddisfly. This breakthrough marks a new frontier in the field of engineered fibers and underscores the Company's commitment to pioneering innovations in biotechnology. Caddisflies (known in the Pacific Northwest as 'Periwinkles') are known for their extraordinary ability to spin silk underwater, which they use to construct protective cases in aquatic environments. By leveraging the unique mechanical and chemical attributes of caddisfly silk proteins, Kraig Labs seeks to engineer materials with unprecedented functionality. This new silk offers the potential for increased durability when submerged in water. Possible applications for this new silk are vast, with exciting potentials for medical adhesives, biomedical textiles, performance apparel, and next-generation fiber technologies. 'This achievement demonstrates our ability to extend beyond spider silk proteins and explore the broader possibilities of silk engineering,' said CEO and Founder of Kraig Labs, Kim Thompson. 'By tapping into the evolutionary diversity of silk-producing organisms, we're expanding the toolkit for creating super fibers that meet the demands of tomorrow's industries.' The introduction of caddisfly-based transgenic fiber represents a critical milestone in the Company's vision to create new super materials blending the physical and chemical properties of various silk proteins. The result is an ever-growing portfolio of high-performance materials designed to redefine the standards of strength, elasticity, and functionality. These new fibers will leverage the Company's propriety silkworm-based production system to bring these materials to market. 'Incorporating the unique and incredible adhesive properties of caddisfly silk protein has been a key part of the R&D roadmap I laid out when founding Kraig Labs,' Thompson continued. 'Unveiling this pivotal scientific milestone, our first caddisfly-based transgenic, marks not only a significant leap forward for the Company's business model but also a deeply gratifying achievement for me personally and for our team.' This breakthrough would not have been possible without the dedication and ingenuity of the Company's scientific team. Their relentless pursuit of excellence and creative problem-solving have once again positioned Kraig Labs at the forefront of biotechnological innovation. 'Our team's success with this caddisfly-inspired material is a testament to the power of combining cutting-edge science with bold vision,' added the Company's COO, Jon Rice. 'We are excited about the potential this fiber holds and the new opportunities it creates across multiple sectors.' Kraig Labs is committed to pushing the boundaries of creativity and science in silk protein engineering. The Company has filed a provisional utility patent application for this exciting new technology. By exploring and integrating the diverse properties of silk from various species, the Company will continue to lead the charge in developing sustainable, high-performance materials that address real-world challenges. For details about other recent advancements that Kraig Labs has made, please watch the Company's investor conference at or on the Company's YouTube Channel About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. ( a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. Cautionary Statement Regarding Forward Looking Information Statements in this press release about the Company's future and expectations other than historical facts are 'forward-looking statements.' These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as 'believes,' 'plans,' 'expects,' 'anticipates,' 'foresees,' 'estimated,' 'hopes,' 'if,' 'develops,' 'researching,' 'research,' 'pilot,' 'potential,' 'could' or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. Ben Hansel, Hansel Capital, LLC
